{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014522","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.779508+00:00","generated_at":"2026-05-30T04:31:55.484048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028","bullets":["Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.","R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.","Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.","First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.","Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014522","json":"https://secwatch.observer/filing/0001558370-24-014522.json","markdown":"https://secwatch.observer/filing/0001558370-24-014522.md","text":"https://secwatch.observer/filing/0001558370-24-014522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/0001558370-24-014522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/acrs-20241106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:31:55.484048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}